Form 8-K

8-K — CorMedix Inc.

Accession: 0001213900-26-066061

Filed: 2026-06-08

Period: 2026-06-08

CIK: 0001410098

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — ea0293895-8k_cormedix.htm (Primary)

EX-99.1 — PRESS RELEASE DATED JUNE 8, 2026 (ea029389501ex99-1.htm)

GRAPHIC (ea029389501_ex99-1img1.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — CURRENT REPORT

8-K (Primary)

Filename: ea0293895-8k_cormedix.htm · Sequence: 1

false

0001410098

2026-06-08

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 or 15(d)

the Securities Exchange Act of 1934

Date

of Report (Date of earliest event reported): June 8, 2026

CORMEDIX INC.

(Exact

name of registrant as specified in its charter)

Delaware

001-34673

20-5894890

(State

or other jurisdiction of

incorporation)

(Commission

File Number)

(IRS

Employer

Identification No.)

389 Interpace Parkway, Suite 450

Parsippany, NJ

07054

(Address

of principal executive offices)

(Zip

Code)

Registrant’s

telephone number, including area code: (908) 517-9500

N/A

(Former

name or former address, if changed since last report)

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions (see General Instruction A.2, below):

☐

Written communications

pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant

to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications

pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications

pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities

registered pursuant to Section 12(b) of the Act:

Title

of each class

Trading

Symbol(s)

Name

of each exchange on which registered

Common stock, $0.001 par value

CRMD

Nasdaq

Global Market

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405

of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging

growth company ☐

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item

7.01 Regulation FD Disclosure

June 8, 2026, CorMedix, Inc. (the “Company”) issued a press release on the decision by the United States Court of Appeals

for the Federal Circuit in Melinta Therapeutics, LLC, et al. v. Nexus Pharmaceuticals, Inc., which affirmed the district court’s

judgment that Nexus Pharmaceuticals Inc.’s generic minocycline product infringed two of the Company’s patents and rejected

Nexus’s invalidity challenge. A copy of the press release is furnished as Exhibit 99.1, attached hereto.

The

information in this Item 7.01 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities

Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall

it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”),

or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Forward-Looking

Statements

This

Current Report on Form 8-K contains “forward-looking statements” within the meaning of the Private Securities Litigation

Reform Act of 1995, Section 27A of the Securities Act, and Section 21E of the Exchange Act, that are subject to risks and uncertainties.

Forward-looking statements are often identified by the use of words such as, but not limited to, “anticipate,” “believe,”

“can,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,”

“plan,” “project,” “seek,” “should,” “target,” “will,” “would,”

and similar expressions or variations intended to identify forward-looking statements. All statements, other than statements of historical

facts, regarding management’s expectations, beliefs, goals, plans or the Company’s prospects should be considered forward-looking

statements. Readers are cautioned that actual results may differ materially from projections or estimates due to a variety of important

factors, and readers are directed to the Risk Factors identified in the Company’s filings with the SEC, including its most recent

Annual Report on Form 10-K, copies of which are available free of charge at the SEC’s website at www.sec.gov or upon request from

the Company. The Company may not actually achieve the goals or plans described in its forward-looking statements, and such forward-looking

statements speak only as of the date of this Current Report on Form 8-K. Investors should not place undue reliance on these statements.

The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.

Item

9.01 Financial Statements and Exhibits

(d)

Exhibits

Exhibit

No.

Description

99.1

Press Release dated June 8, 2026

104

Cover Page Interactive Data File (embedded within the

Inline XBRL document)

SIGNATURE

Pursuant

to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by

the undersigned hereunto duly authorized.

CORMEDIX INC.

Date: June 8, 2026

By:

/s/

Joseph Todisco

Name:

Joseph Todisco

Title:

Chief Executive Officer

EX-99.1 — PRESS RELEASE DATED JUNE 8, 2026

EX-99.1

Filename: ea029389501ex99-1.htm · Sequence: 2

Exhibit

99.1

U.S.

COURT OF APPEALS FOR THE FEDERAL CIRCUIT AFFIRMS VICTORY FOR CORMEDIX THERAPEUTICS IN MINOCIN® PATENT LITIGATION

Parsippany,

NJ – June 8, 2026 – CorMedix Therapeutics (Nasdaq: CRMD) today announced that

the United States Court of Appeals for the Federal Circuit has affirmed the judgment of the U.S. District Court for the Northern District

of Illinois that the patents covering its product MINOCIN® for Injection are valid and infringed by the product developed by Nexus

Pharmaceuticals, Inc.

Following

a four-day bench trial in 2023, the district court found in favor of CorMedix’s wholly owned subsidiary Melinta Therapeutics on

all patent infringement and validity issues. The Federal Circuit’s decision on Friday upheld the district court’s findings

that Nexus’ proposed generic minocycline product infringes the MINOCIN® patents and rejected Nexus’ invalidity challenge.

The Federal Circuit also affirmed the district court’s permanent injunction barring Nexus from marketing its generic product prior

to patent expiration. The patents-at-issue are FDA Orange Book listed and protect the company’s innovative reformulation of intravenous

minocycline, marketed as MINOCIN® for Injection. MINOCIN® is a tetracycline derived antibiotic used primarily in hospital and

acute care settings for patients with a variety of serious and drug-resistant infections.

“We

are pleased that the Federal Circuit has affirmed the district court’s thorough and well-reasoned decision,” said Joseph

Todisco, CorMedix Chairman and CEO. “This ruling validates the strength of the MINOCIN® intellectual property portfolio and

recognizes the innovative work that led to important improvements in intravenous minocycline therapy for patients. The decision reinforces

the importance of protecting pharmaceutical innovation and the substantial investments required to develop improved therapies. We will

continue to protect and defend CorMedix’s intellectual property.”

About

CorMedix

Therapeutics is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment

of life-threatening conditions and diseases in the United States. CorMedix is focused on selling and marketing products in institutional

settings of care in the US and has field based medical and commercial infrastructure deployed in hospitals, clinics and infusion centers.

For more information visit: www.cormedix.com.

Forward-Looking

Statements

This

press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act

of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended,

as amended (the “Exchange Act”), that are subject to risks and uncertainties. Forward-looking statements are often

identified by the use of words such as, but not limited to, “anticipate,” “believe,” “can,”

“continue,” “could,” “estimate,” “expect,” “intend,” “may,”

“plan,” “project,” “seek,” “should,” “target,” “will,”

“would,” and similar expressions or variations intended to identify forward-looking statements. All statements, other

than statements of historical facts, regarding management’s expectations, beliefs, goals, plans or CorMedix’s prospects

should be considered forward-looking statements including, but not limited to statements regarding financial and business guidance;

sales, revenue and operating expense estimates; synergy estimates and timing; accretion estimates and Adjusted EBITDA estimates. Readers are cautioned that actual results may

differ materially from projections or estimates due to a variety of important factors, and readers are directed to the Risk Factors

identified in CorMedix’s filings with the SEC, including its most recent Annual Report on Form 10-K, copies of which are

available free of charge at the SEC’s website at www.sec.gov or upon request from CorMedix. CorMedix may not actually achieve

the goals or plans described in its forward-looking statements, and such forward-looking statements speak only as of the date of

this press release. In addition, pro forma financial information does not necessarily reflect the actual results that we would have

achieved had the pro forma transaction been consummated as of the date indicated nor does it reflect the potential future results of

the combined company. Investors should not place undue reliance on these statements. CorMedix assumes no obligation and does not

intend to update these forward-looking statements, except as required by law.

Investor

Contact:

Dan

Ferry

Managing

Director

LifeSci

Advisors

daniel@lifesciadvisors.com

(617)

430-7576

GRAPHIC

Filename: ea029389501_ex99-1img1.jpg · Sequence: 3

Binary file (18616 bytes)

Download ea029389501_ex99-1img1.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.1

Cover

Jun. 08, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Jun. 08, 2026

Entity File Number

001-34673

Entity Registrant Name

CORMEDIX INC.

Entity Central Index Key

0001410098

Entity Tax Identification Number

20-5894890

Entity Incorporation, State or Country Code

Entity Address, Address Line One

389 Interpace Parkway

Entity Address, Address Line Two

Suite 450

Entity Address, City or Town

Parsippany

Entity Address, State or Province

Entity Address, Postal Zip Code

07054

City Area Code

908

Local Phone Number

517-9500

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common stock, $0.001 par value

Trading Symbol

CRMD

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration